Daily Treatment with SMT C1100 Reduces Dystrophic Symptoms in Mice
Author Information
Author(s): Tinsley Jonathon M., Fairclough Rebecca J., Storer Richard, Wilkes Fraser J., Potter Allyson C., Squire Sarah E., Powell Dave S., Cozzoli Anna, Capogrosso Roberta F., Lambert Adam, Wilson Francis X., Wren Stephen P., De Luca Annamaria, Davies Kay E.
Primary Institution: Summit plc, Abingdon, United Kingdom
Hypothesis
The hypothesis to protect myofibres from damage in the absence of dystrophin is that utrophin, if continually localised to the sarcolemma, will replace dystrophin function.
Conclusion
SMT C1100 significantly reduces dystrophic symptoms and improves muscle function in mdx mice, suggesting its potential as a treatment for Duchenne muscular dystrophy.
Supporting Evidence
- SMT C1100 treatment resulted in a two-fold increase in utrophin mRNA in mdx mice.
- Mice treated with SMT C1100 showed significant reductions in muscle degeneration.
- The drug improved muscle strength and resistance to fatigue in treated mice.
Takeaway
Researchers found that a new drug called SMT C1100 helps mice with a muscle disease feel stronger and less tired.
Methodology
The study involved treating mdx mice with SMT C1100 and assessing muscle function and pathology through various tests.
Potential Biases
Potential conflicts of interest due to authors' affiliations with Summit plc.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
Mice used were male mdx mice, aged 3 weeks at the start of treatment.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website